Ligand Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
LGND Ligand Pharmaceuticals Inc
MRAM Everspin Technologies Inc
LULU Lululemon Athletica Inc
SSYS Stratasys Ltd
ASTE Astec Industries Inc
NHTC Natural Health Trends Corp
DB Deutsche Bank AG
XPER Xperi Holding Corp
TT Trane Technologies PLC
UAA Under Armour Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Closing Price
$130.20
Day's Change
-1.82 (-1.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
133.47
Day's Low
129.00
Volume
(Heavy Day)
Volume:
171,222

10-day average volume:
124,869
171,222

Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Valuation Ratios

Price/Earnings (TTM)
57.04x
Price/Sales (TTM)
10.55x
Price/Book (MRQ)
2.94x
Price/Cash Flow (TTM)
29.99x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

April 2021
Current Month
1.6M
Previous Month
1.5M
Percent of Float
9.92%
Days to Cover
13.5533 Days

Share Information

LGND is in a share class of common stock
Float
15.3M
Shares Outstanding
16.7M
Institutions Holding Shares
353
133.51%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • John W. Kozarich
  • Matthew W. FoehrPres.
  • John L. HigginsCEO
  • Matthew E. KorenbergCFO
  • Charles S. BerkmanSr.VP

Address

  • 3911 Sorrento Valley Blvd Ste 110
  • San Diego, CA 92121-1402
  • Phone: (858) 550-7500
  • Fax: (302) 636-5454
  • https://www.ligand.com/

Insider Trading

During the most recent quarter, 227K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.